$SVRA
Savara Inc

2022 Q1 Form 10-K Financial Statement

#000095017022005045 Filed on March 30, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.354M $3.019M $12.35M
YoY Change -15.32% 8.21% -13.39%
% of Gross Profit
Research & Development $5.684M $7.618M $28.99M
YoY Change -25.1% -25.02% -17.26%
% of Gross Profit
Depreciation & Amortization $8.000K $2.000K $100.0K
YoY Change -84.0% -97.14% -66.67%
% of Gross Profit
Operating Expenses $8.046M $10.64M $41.48M
YoY Change -22.74% -18.22% -16.3%
Operating Profit -$8.046M -$41.48M
YoY Change -22.74% -15.87%
Interest Expense -$570.0K -$642.0K -$2.282M
YoY Change -3.88% -12.05% 53.98%
% of Operating Profit
Other Income/Expense, Net -$254.0K -$29.00K -$1.537M
YoY Change -228.93% 387.94%
Pretax Income -$8.300M -$11.31M -$43.01M
YoY Change -18.79% -17.69% -13.3%
Income Tax
% Of Pretax Income
Net Earnings -$8.300M -$11.31M -$43.01M
YoY Change -18.76% -17.69% -13.3%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.32
Diluted Earnings Per Share -$54.33K -$84.45K -$321.2K
COMMON SHARES
Basic Shares Outstanding 114.0M 113.9M 133.9M
Diluted Shares Outstanding 152.8M 133.9M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $151.8M $161.2M $161.2M
YoY Change -21.23% 96.07% 96.07%
Cash & Equivalents $79.20M $34.01M $34.01M
Short-Term Investments $72.57M $127.2M $127.2M
Other Short-Term Assets $1.591M $2.685M $2.685M
YoY Change 165.17% 123.75% 123.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $154.5M $165.0M $165.0M
YoY Change -20.67% 93.84% 93.89%
LONG-TERM ASSETS
Property, Plant & Equipment $64.00K $73.00K $373.0K
YoY Change -36.0% -53.21% -6.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $548.0K $251.0K -$49.00K
YoY Change -45.2% 0.4% -149.0%
Total Long-Term Assets $11.67M $11.60M $11.60M
YoY Change -8.81% -8.13% -7.95%
TOTAL ASSETS
Total Short-Term Assets $154.5M $165.0M $165.0M
Total Long-Term Assets $11.67M $11.60M $11.60M
Total Assets $166.2M $176.6M $176.6M
YoY Change -19.94% 80.67% 80.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.296M $1.443M $1.443M
YoY Change -52.0% -44.39% -44.5%
Accrued Expenses $2.527M $4.884M $4.884M
YoY Change -43.64% -12.46% -12.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.50M $8.333M $8.333M
YoY Change
Total Short-Term Liabilities $16.32M $14.66M $14.66M
YoY Change 126.49% 79.35% 78.78%
LONG-TERM LIABILITIES
Long-Term Debt $13.31M $17.32M $17.32M
YoY Change -47.28% -31.0% -30.98%
Other Long-Term Liabilities $102.0K $117.0K $117.0K
YoY Change 75.86% 39.29% 17.0%
Total Long-Term Liabilities $13.41M $17.44M $17.44M
YoY Change -47.0% -30.76% -30.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.32M $14.66M $14.66M
Total Long-Term Liabilities $13.41M $17.44M $17.44M
Total Liabilities $29.73M $32.10M $32.10M
YoY Change -8.54% -3.78% -3.89%
SHAREHOLDERS EQUITY
Retained Earnings -$308.8M -$300.5M
YoY Change 15.35% 16.7%
Common Stock $445.6M $445.0M
YoY Change 38.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $136.5M $144.5M $144.5M
YoY Change
Total Liabilities & Shareholders Equity $166.2M $176.6M $176.6M
YoY Change -19.94% 80.67% 80.76%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$8.300M -$11.31M -$43.01M
YoY Change -18.76% -17.69% -13.3%
Depreciation, Depletion And Amortization $8.000K $2.000K $100.0K
YoY Change -84.0% -97.14% -66.67%
Cash From Operating Activities -$8.400M -$9.363M -$40.10M
YoY Change -12.47% -23.88% 0.66%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $57.00K
YoY Change 21.28%
Acquisitions
YoY Change
Other Investing Activities $53.67M -$1.228M -$69.40M
YoY Change -169.03% 231.89% -661.94%
Cash From Investing Activities $53.67M -$1.268M -$69.46M
YoY Change -169.03% 233.68% -867.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K 6.000K 120.8M
YoY Change -100.0% 3174.76%
NET CHANGE
Cash From Operating Activities -8.400M -9.363M -40.10M
Cash From Investing Activities 53.67M -1.268M -69.46M
Cash From Financing Activities -1.000K 6.000K 120.8M
Net Change In Cash 45.22M -10.63M 11.13M
YoY Change 36.59% -16.21% -141.35%
FREE CASH FLOW
Cash From Operating Activities -$8.400M -$9.363M -$40.10M
Capital Expenditures -$40.00K $57.00K
Free Cash Flow -$9.323M -$40.16M
YoY Change -24.2% 0.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001160308
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 svra Minimum Percentage Points Change In Ownership Interest
MinimumPercentagePointsChangeInOwnershipInterest
0.0050
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-32157
CY2021 dei Entity Registrant Name
EntityRegistrantName
Savara Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1318182
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
6836 Bee Cave Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
CY2021 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 201
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2021 dei City Area Code
CityAreaCode
512
CY2021 dei Local Phone Number
LocalPhoneNumber
614-1848
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
SVRA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
179511384
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114039860
CY2021 dei Auditor Firm
AuditorFirmId
49
CY2021 dei Auditor Name
AuditorName
RSM US LLP
CY2021 dei Auditor Location
AuditorLocation
Austin, Texas
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34012000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22880000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
127159000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
59308000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3829000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2933000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
165000000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
85121000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2021Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11274000
CY2020Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
12218000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
251000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2021Q4 us-gaap Assets
Assets
176598000
CY2020Q4 us-gaap Assets
Assets
97745000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1443000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2595000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4884000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8333000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14660000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8174000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17323000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25104000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
117000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000
CY2021Q4 us-gaap Liabilities
Liabilities
32100000
CY2020Q4 us-gaap Liabilities
Liabilities
33362000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114036892
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114036892
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54152955
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54152955
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
116000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444898000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
320893000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-300521000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257507000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
144498000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
176598000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97745000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
257000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
28991000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
35038000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12350000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14264000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
136000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
255000
CY2021 us-gaap Operating Expenses
OperatingExpenses
41477000
CY2020 us-gaap Operating Expenses
OperatingExpenses
49557000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41477000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-49300000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2282000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1482000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-99000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
158000
CY2021 svra Tax Credit Income
TaxCreditIncome
844000
CY2020 svra Tax Credit Income
TaxCreditIncome
893000
CY2020 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
116000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1537000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-315000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43014000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49615000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
133919145
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59309090
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-887000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1006000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43951000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48656000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
101698000
CY2020 svra Stock Issued During Period Value Licensing Of Assets
StockIssuedDuringPeriodValueLicensingOfAssets
2120000
CY2020 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
2290000
CY2020 svra Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Milestone Warrants Net
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet
1827000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88000
CY2020 svra Adjustments To Additional Paid In Capital Closing Costs For Previous Issuance Of Securities In Private Placement
AdjustmentsToAdditionalPaidInCapitalClosingCostsForPreviousIssuanceOfSecuritiesInPrivatePlacement
120000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
29000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5107000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1006000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49615000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
122231000
CY2021 svra Adjustment To Additional Paid In Capital Repurchase Of Pre Funded Warrants
AdjustmentToAdditionalPaidInCapitalRepurchaseOfPreFundedWarrants
3909000
CY2021 svra Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
2546000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
78000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3260000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-887000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43014000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
144498000
CY2021 us-gaap Profit Loss
ProfitLoss
-43014000
CY2020 us-gaap Profit Loss
ProfitLoss
-49615000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
136000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
255000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1969000000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2470000000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
231000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
438000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5367000
CY2020 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
116000
CY2021 svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
-103000
CY2020 svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
29000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-99000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
158000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
552000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
507000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1604000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-55000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3260000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5107000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1039000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
134000
CY2021 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-1763000
CY2020 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-1140000
CY2021 svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-44000
CY2020 svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-431000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40081000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39836000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
CY2020 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3247000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
161069000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
86083000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
83470000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
89650000
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8200000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8780000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69456000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9053000
CY2021 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
3909000
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
514000
CY2021 svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
122231000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2290000
CY2021 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
2546000
CY2020 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
1827000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000
CY2021 svra Repurchase Of Shares For Minimum Tax Withholdings
RepurchaseOfSharesForMinimumTaxWithholdings
78000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120806000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3689000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-137000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
170000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11132000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26924000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22880000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49804000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34012000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22880000
CY2020 svra Common Stock Issued For Acquired In Process Research And Development Net
CommonStockIssuedForAcquiredInProcessResearchAndDevelopmentNet
2120000000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-300500000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40100000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34000000.0
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
127200000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management’s estimates include those related to the accrual of research and development and general and administrative costs, certain financial instruments recorded at fair value, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates.</span></p>
CY2021 svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and short-term investments held in money market accounts. The Company places its cash and cash equivalents and money market accounts with a limited number of financial institutions and at times may exceed the amount of insurance provided on such deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2933000
CY2021Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
306000
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
653000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
427000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
453000
CY2021Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
356000
CY2020Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
194000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3829000
CY2021Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
1902000
CY2020Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
591000
CY2021Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
838000
CY2020Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1042000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1920000
CY2021Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1623000
CY2020Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2627000
CY2021Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
600000
CY2020Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
853000
CY2021Q4 svra Accrued Lease Liability
AccruedLeaseLiability
135000
CY2020Q4 svra Accrued Lease Liability
AccruedLeaseLiability
179000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4884000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
127206000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
127159000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59307000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59308000
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2152000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2129000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2079000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1973000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2021 us-gaap Depreciation
Depreciation
100000
CY2020 us-gaap Depreciation
Depreciation
300000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8333000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
18167000
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2021Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
694000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
85000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
65000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
25656000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8333000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17323000
CY2020Q4 svra Upfront Cash Payment Payable
UpfrontCashPaymentPayable
3300000
CY2020 svra Upfront Payment Common Stock Shares Issued
UpfrontPaymentCommonStockSharesIssued
1000000
CY2020 svra Upfront Payment Common Stock Issued Value
UpfrontPaymentCommonStockIssuedValue
2100000
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11300000
CY2021 svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
-900000
CY2020 svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
1100000
CY2019Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25247000
CY2021 svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
129968000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
7737000
CY2021 svra Net Proceeds After Deducting Underwriting Discounts Commissions And Offering Expenses
NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses
122231000
CY2021 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2021Q4 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
301000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114036892
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54152955
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
46299718
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
45133986
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
38808502
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
959000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-937000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5000
CY2021 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company’s leases have lease terms that include options to extend (in some cases, for up to 36 months). The exercise of lease renewal and termination options are at the Company’s sole discretion. For purposes of calculating operating lease liabilities, the Company’s leases are deemed not to include an option to extend the lease term until it is reasonably certain that the Company will exercise that option. The Company has operating lease agreements with lease and non-lease components that are accounted for as a single lease component.
CY2021 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2021 svra Sublease Expiry Month And Year
SubleaseExpiryMonthAndYear
2021-07
CY2021 svra Operating Lease Termination Period
OperatingLeaseTerminationPeriod
The Company also terminated a lease agreement during the fourth quarter of 2021
CY2021Q4 svra Lease Termination Fee Paid
LeaseTerminationFeePaid
20000
CY2021Q4 svra Reduction Of Right Of Use Operating Lease Assets Due To Termination Of Lease Agreement
ReductionOfRightOfUseOperatingLeaseAssetsDueToTerminationOfLeaseAgreement
100000
CY2021Q4 svra Reduction Of Operating Lease Liabilities Due To Termination Of Lease Agreement
ReductionOfOperatingLeaseLiabilitiesDueToTerminationOfLeaseAgreement
100000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
135000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
63000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
252000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
231000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
241000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P26M15D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
300000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
200000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
CY2021 svra Decrease In Milestone Payment Related To The Removal Of Nebulizer System
DecreaseInMilestonePaymentRelatedToTheRemovalOfNebulizerSystem
5000000.0
CY2021 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
2866000
CY2021 svra Research And Development Expense For Termination
ResearchAndDevelopmentExpenseForTermination
800000
CY2021Q1 svra Estimated Parexel Service Fees And Pass Through Expenses
EstimatedParexelServiceFeesAndPassThroughExpenses
32000000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6240343
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M7D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
190000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2060000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.23
CY2021 svra Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P6Y21D
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
889178
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.38
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
574000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1192324
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.25
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6218841
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.25
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
354000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2279007
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.70
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y5M23D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
69000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1250000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.19
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
443897
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6218841
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.25
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y7M2D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
354000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
509397
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.78
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.35
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
29376
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
43125
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
6.06
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1272375
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.20
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3260000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5107000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-28705000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30396000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-14309000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-19219000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43014000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49615000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9033000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10419000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-12253000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13355000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1966000
CY2020 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2020Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1332000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4351000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
17620000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1904000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
68000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-177000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-205000
CY2021 svra Effective Income Tax Rate Reconciliation Net Operating Loss Carryforward Limitation
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwardLimitation
25249000
CY2021 svra Income Tax Reconciliation Foreign Deferred Tax Asset True Up
IncomeTaxReconciliationForeignDeferredTaxAssetTrueUp
-3833000
CY2021 svra Income Tax Reconciliation Imputed Interest
IncomeTaxReconciliationImputedInterest
1253000
CY2021 svra Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
738000
CY2020 svra Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
-760000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
22000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-135000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-10900000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14300000
CY2021 svra Effective Income Tax Rate Reconciliation Net Operating Loss Carryforward Limitation
EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryforwardLimitation
25200000
CY2021 svra Valuation Allowance Deferred Tax Asset Increase By Offset Amount
ValuationAllowanceDeferredTaxAssetIncreaseByOffsetAmount
13200000
CY2021 svra Valuation Allowance Deferred Tax Asset Due To Foreign Transalation Adjustments
ValuationAllowanceDeferredTaxAssetDueToForeignTransalationAdjustments
1100000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
574000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
524000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
574000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
524000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36298000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38256000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5380000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
230000
CY2021Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1212000
CY2021Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
1107000
CY2020Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
1806000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
48348000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59244000
CY2021Q4 svra Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
47774000
CY2020Q4 svra Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
58720000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47774000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58720000
CY2021Q4 svra Percentage Increase In Shareholders Ownership Interest
PercentageIncreaseInShareholdersOwnershipInterest
0.05
CY2021 svra Change In Ownership Interest Period
ChangeInOwnershipInterestPeriod
P3Y
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
71800000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
54800000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3600000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2900000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7569009
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38578449
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-43014000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49615000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43014000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49615000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-43014000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-49615000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
133919145
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59309090
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84

Files In Submission

Name View Source Status
0000950170-22-005045-index-headers.html Edgar Link pending
0000950170-22-005045-index.html Edgar Link pending
0000950170-22-005045.txt Edgar Link pending
0000950170-22-005045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img196269655_0.jpg Edgar Link pending
img196269655_1.jpg Edgar Link pending
img196269655_2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-20211231.htm Edgar Link pending
svra-20211231.xsd Edgar Link pending
svra-20211231_cal.xml Edgar Link unprocessable
svra-20211231_def.xml Edgar Link unprocessable
svra-20211231_htm.xml Edgar Link completed
svra-20211231_lab.xml Edgar Link unprocessable
svra-20211231_pre.xml Edgar Link unprocessable
svra-ex10_16.htm Edgar Link pending
svra-ex10_17.htm Edgar Link pending
svra-ex21_1.htm Edgar Link pending
svra-ex23_1.htm Edgar Link pending
svra-ex31_1.htm Edgar Link pending
svra-ex31_2.htm Edgar Link pending
svra-ex32_1.htm Edgar Link pending